Kintara Therapeutics to Participate in Benzinga Biotech Small Cap Conference March 17, 2021 • 8:00 AM EDT
Kintara Therapeutics to Participate in Maxim Group's 2021 Emerging Growth Virtual Conference March 10, 2021 • 8:00 AM EST
Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer March 3, 2021 • 8:00 AM EST
Kintara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference March 2, 2021 • 8:00 AM EST
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM February 17, 2021 • 8:00 AM EST
Kintara Therapeutics Announces Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update February 12, 2021 • 8:30 AM EST
Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer February 3, 2021 • 5:15 PM EST
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial January 13, 2021 • 8:00 AM EST
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial January 6, 2021 • 1:00 PM EST
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference January 5, 2021 • 8:00 AM EST